secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVO Fertility, Inc. (IVF)
CIK:        0001417926
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001493152-23-017342
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INVO Bioscience Q1 2023 revenue up 114% to $348k; gross margin improves to 79%
------------------------------------------------------------------------------

- Revenue $348,025 (+114% YoY); consolidated clinic revenue $297,381 (+181% YoY).
- Gross margin 79% vs 60% in Q1 2022; adjusted EBITDA loss narrowed to $(1.7)M from $(2.0)M.
- All-clinic combined revenue $646,707 (+108% YoY); existing centers nearing break-even.
- Acquisition of Wisconsin Fertility Institute for $10M payable over 3 years; closing expected Q2 2023.
- Raised ~$3M in registered direct offering; cash balance $2.2M as of March 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417926/000149315223017342/0001493152-23-017342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417926/000149315223017342/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-017342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer